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Summary A prominent feature of several type of cancer is cachexia. This syndrome causes a marked loss of lean body mass and muscle
wasting, and appears to be mediated by cytokines and tumour products. There are several proteases and proteolytic pathways that could be
responsible for the protein breakdown. In the present study, we investigated whether caspases are involved in the proteolytic process of
skeletal muscle catabolism observed in a murine model of cancer cachexia (MAC16), in comparison with a related tumour (MAC13), which
does not induce cachexia. Using specific peptide substrates, there was an increase of 54% in the proteolytic activity of caspase-1, 84% of
caspase-8, 98% of caspase-3 151% to caspase-6 and 177% of caspase-9, in the gastrocnemius muscle of animals bearing the MAC16
tumour (up to 25% weight loss), in relation to muscle from animals bearing the MAC13 tumour (1–5% weight loss). The dual pattern of 89 kDa
and 25 kDa fragmentation of poly (ADP-ribose) polymerase (PARP) occurred in the muscle samples from animals bearing the MAC16 tumour
and with a high amount of caspase-like activity. Cytochrome c was present in the cytosolic fractions of gastrocnemius muscles from both
groups of animals, suggesting that cytochrome c release from mitochondria may be involved in caspase activation. There was no evidence
for DNA fragmentation into a nucleosomal ladder typical of apoptosis in the muscles of either group of mice. This data supports a role
for caspases in the catabolic events in muscle involved in the cancer cachexia syndrome. © 2001 Cancer Research Campaign
http://www.bjcancer.com
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doi: 10.1054/ bjoc.2001.1700, available online at http://www.idealibrary.com on http://www.bjcancer.comCancer cachexia is a complex metabolic problem characterized by
weight loss with depletion of both skeletal muscle and adipose
tissue (Tisdale, 1997). 
A number of studies have suggested the cytokines: interleukin-1
(IL-1), interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α)
as mediators of cancer cachexia. In addition proteolysis-inducing
factor (PIF) isolated from a cachexia-inducing murine tumour is
capable of inducing protein degradation both in skeletal muscles in
vivo and in vitro (Todorov et al, 1996; Lorite et al, 1997). Different
proteolytic systems and enzymes may contribute to this increase,
including the lysosomal proteases, cathepsin B and L, the
Ca2+ dependent cytosolic proteases, calpains, and the ubiquitin-
proteasome pathway (Tisdale, 1997; Lecker et al, 1999).
Nevertheless, other proteolytic enzymes or processes that modulate
tissue and cell homeostasis under the influence of growth-hormonal
factors, may participate to some extent in skeletal muscle catabolism. 
Caspases are a structurally related group of cysteine proteases
that cleave peptide bonds following aspartate residues (Cryns and
Yuan, 1998; Thornberry and Lazebnik, 1998). They play a central
role in activating the apoptotic cell death machinery. In mammals,
at least 14 different caspases have been described. They are divided
into three subclasses: inflammatory, initiator and executioner,
according to their function and primary sequence. Caspases-8 and 
-10 contain tandem repeats called ‘death effector domain’ (DED)1135
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‘caspase recruitment domain’ called CARD. Both types of domain
recruit caspases to their activator complexes, named apoptosoma.
DED-containing caspases are activated through DED-containing
death receptor-associated proteins FADD and TRADD, after the
cytokine binding to TNFR1 receptor, Fas/APO receptor, and
related death receptors (Ashkenazi and Dixit, 1998). Many apop-
totic stimuli lead to the release of cytochrome c from mitochondria.
Binding of cytochrome c and dATP to Apaf-1 in the cytoplasm
enables Apaf-1 to associate with its CARD domain of procaspase-
9, thereby triggering the activation of a caspase-9 initiated prote-
olytic cascade (Mignotte and Vayssiere, 1998). Both of these
caspase-activating pathways have multiple positive and negative
endogeneous regulators, including the proteins in the families Bcl-
2, Bax and IAP (Adams and Cory, 1998; Cryns and Yuan, 1998).
During apoptosis, a select set of proteins is cleaved by caspases,
usually at a single site, resulting in a loss or change in function
(Cryns and Yuan, 1998). 
Potent, specific peptide substrates and inhibitors have been
developed and widely used to confirm the relative contribution of
a particular caspase in cellular functions (Alnemri, 1997;
Livingstone, 1997; Villa et al, 1997). Although caspase activation
occurs mainly during apoptotic cell death, recent evidence
supports a role for these proteases in the activation and prolifera-
tion events of phytohaemagglutinin-stimulated human T lympho-
cytes (Miossec et al, 1997). In the present study, we investigated
whether caspases are involved in the proteolytic process of
skeletal muscle catabolism observed in a cancer cachexia mouse
model (MAC16) in comparison with a related tumour which does
1136 JE Belizário et al not produce cachexia (MAC13) (Beck and Tisdale, 1987). 
MATERIALS AND METHODS 
Reagents 
The fluorogenic substrates and peptide inhibitors, respectively, were 
as follows: caspases-1, Ac-YVAD-AMC, Z-VAD-FMK; caspase-2, 
Z-VDVAD-AFC, Z-VAD-FMK; caspase-3, Ac-DEVD-AMC, Z-
DEVD-FMK; caspase-8, Z-IEDT-AFC, Z-IEDT-FMK; caspase-
9, Ac-LEHD-AFC, Z-VAD-FMK. Fluorometric standard: 7-
amino-4-trifluoromethyl coumarin (AFC) and amino-4-methyl-
coumarin (AMC). All products were purchased from Calbiochem-
Novabiochem Corp, La Jolla, CA, USA. Stock solutions were
prepared in DMSO. 
Animal model for cancer cachexia 
Pure strain NMRI mice were obtained from our own breeding
colony. Fragments of the MAC13 tumour or the MAC16 tumour
less than 2 mm diameter, and excised from donor animals with
established weight loss were implanted into the flanks of mice
(minimum weight 20 g) by means of a trocar under brief general
anaesthesia as described (Beck and Tisdale, 1987). Mice bearing
the MAC16 tumour were terminated by a Schedule 1 method at
various extents of weight loss up to 25%. The gastrocnemius
muscles were removed from both groups of animals and kept at 
–70˚C until assayed. 
Proteolytic activity for caspase-like proteases 
The assay has been adapted from the method published by
Thornberry (1994). Fragments of the gastrocnemius muscle were
cut and immersed in 100 mM HEPES, pH 7.5, 10% sucrose, 0.1%
NP-40, 10 mM DTT and the protease inhibitors (phenylmethyl-
sulphonyl fluoride, PMSF), pepstatin A, bestatin, leupeptin, apro-
tinin, E64, (Sigma protease inhibitor cocktail). The samples were
lysed and homogenized in a Dounce homogenizer, followed by 
3 cycles of freezing in liquid nitrogen and thawing at 4˚C. 
The homogenates were centrifuged at 12 000 rpm for 30 min. 
The amount of protein in the supernatant was determined by the
Bradford Method (Bradford, 1976). 
The enzymatic reaction was performed in duplicate by in-
cubating 80–130 µg of protein with 100 mM HEPES buffer, pH 7.5,
10 mM dithiothreitol (DTT), in a total volume of 1.5 ml. After 
15 min of pre-incubation at 37˚C, the sample was transferred to a
cuvette and 10–50 µM of substrate was added. The reaction was
monitored continuously during 15 min or 30 min in a Hitachi 
F-2000 fluorometer using an excitation wavelength of 380/400 nm
and an emission wavelength of 460/505 nm, as appropriate. The
fluorescence of the cleaved substrate was compared with that
observed in the presence of 100× concentration of a caspase
inhibitor, either with a wide spectrum or one selective for each
capase (see list in Reagents). The proteolytic activity (U min–1)
was calcualted using the following formula: [FU1–FU0/T1–T0] × 60,
which represents the difference in fluorescence units (FU)
between time initial (T0) and final (T1) of the reaction. 
DNA extraction and agarose gel electrophoresis 
The method used is an adaptation of that published by Tilly et alBritish Journal of Cancer (2001) 84(8), 1135–1140(1991). The fragments of gastrocnemius muscle were homoge-
nized in 400 µl of 0.1 M NaCl, 10 mM EDTA, 0.3 M Tris-HCl, pH
8.0, 0.2 M sucrose, and 0.01% SDS in Eppendorf tubes and
incubated for 1 h in a water bath at 65˚C. Next, 70 µl of 8 M potas-
sium acetate was added and the preparation was incubated on ice for
60 min and centrifuged at 3000 g for 10 min at 4˚C. The upper
phase was transferred to a new tube and DNA extraction was
performed with 1 volume of phenol:chloroform:isoamylalcohol
solution (25:24:1) and precipitated with 2 volumes of 100%
ethanol overnight at –70˚C. DNA was quantified by spectrophoto-
metry at 260/280 nm. Aliquots of DNA (5–10 µg) were electro-
phoresed on a 2% agarose gel with ethidium bromide and the
DNA bands were photographed by UV transilumination. The λ
DNA/Hind III fragments were used as a DNA molecular marker. 
Western blotting and immunodetection for PARP 
Fragments of the gastrocnemius muscle were homogenized in
HEPES buffer as described above. Equal amount of proteins (120
µg per lane) was analysed by SDS-PAGE, 12.5% polyacrylamide,
and Western blotting onto PVDF membranes. The blot was in-
cubated with rabbit polyclonal antibody for PARP (Santa Cruz
Biotecnology, Santa Cruz, CA, USA), diluted 1:500, and with
horseradish peroxidase-conjugated goat anti-rabbit IgG diluted
1:3000 (Vector Lab., Burlingame, CA, USA). The proteins were
visualized using an ECL detection system (Amersham Pharmacia
Biotech, Bucks, UK). 
Preparation of cytosolic fractions and Western blotting
for cytochrome c 
Fragments of the gastrocnemius muscle were incubated for 30 min
on ice in 300 µl lysis buffer (68 mM sucrose, 200 mM mannitol,
50 mM KCl, 1 mM EGTA, 1 mM EDTA, 1 mM DTT and protease
inhibitor cocktail) (Sigma). The fragments were homogenized
with 80 strokes of a Dounce homogenizer and centrifuged at
800 rpm for 5 min at 4˚C. The supernatant  was centrifuged at
12 000 rpm for 10 min. The supernatant (cytosolic fraction) and
pellet (mitochondria) were separated. The proteins in the cytosolic
fraction (50 µg lane) were electrophoresed in a 20% SDS-PAGE
gel and transferred onto a PVDF membrane. The primary antibody
was mouse monoclonal anti-cytochrome c  diluted 1:2500
(7H8.2C12; Pharmingen, San Diego, CA, USA) and the secondary
antibody was biotinylated goat anti-mouse Ig (1:3000) (Sigma
Chemical Co., Dorset, UK). Detection was by enhanced chemilu-
minescence (ECL) system (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
Statistical analysis
Results are reported as mean 6 SD. Comparisons of groups was
made by Student’s t test. A 5% difference was considered significant.
RESULTS 
Increase of the proteolytic activity to caspase substrates
in lysates of skeletal muscle from cachectic mice 
In previous studies, it has been shown that mice bearing the
MAC16 tumour have an increased proteolytic activity in skeletal
muscle as compared with mice bearing the MAC13 tumour (Beck© 2001 Cancer Research Campaign
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Table 1 Proteolytic cleavage of caspases 1, 3, 6, 8 and 9 substrates by proteases in the protein lysates of gastrocnemius
muscles from mice bearing the MAC 13 and MAC 16 tumours
No. Tumour Weight Loss (%) Proteolytic activity
(U min–1) Mean 6 SD (% increase)
CASPASE-1
1 MAC13 2 0.81
7 MAC13 3 2.30
13 MAC13 5 2.10 1.73 6 0.80
2 MAC16 15 3.37
14 MAC16 25 2.30
15 MAC16 25 2.20 2.62 6 0.64 (54%)
CASPASE-9
1 MAC13 2 0.73
7 MAC13 3 0.79
13 MAC13 5 0.66 0.72 6 0.06
2 MAC16 15 1.42
14 MAC16 25 2.60
15 MAC16 25 1.99 2.00 6 0.59 a (177%)
CASPASE-8
1 MAC13 2 1.20
7 MAC13 3 0.80
13 MAC13 5 0.60 0.95 6 0.30
2 MAC16 15 1.65
14 MAC16 25 2.10
15 MAC16 25 1.50 1.75 6 0.31a (84%)
CASPASE-3
1 MAC13 2 1.50
7 MAC13 3 4.50
13 MAC13 5 5.25 3.75 6 1.9
2 MAC16 15 5.00
14 MAC16 25 9.45
15 MAC16 25 8.85 7.76 6 2.4a (98%)
CASPASE-6
1 MAC13 2 3.67
7 MAC13 3 3.04 
13 MAC13 5 1.34 2.68 ± 1.2 
2 MAC16 15 8.88 
14 MAC16 25 4.06 
15 MAC16 25 7.26 6.73 ± 2.4* (151%) 
The proteolytic activity was determined by incubation of 40 µg (caspase-1), 80 µg (caspase-8) or 130 µg (caspase-3, -6, -9) of
skeletal muscle protein with 15–50 µM of the caspase fluorogenic substrate for the caspase indicated, with or without the
caspase inhibitors Z-VAD-fmk (caspase-6), IEDT-fmk (caspase-8), LEHD-CHO (caspase-9) or DVED-fmk (caspase-3).
Release of AMC/AFC was monitored during 15–30 min at 37˚C on a fluorimeter (Hitachi). One unit represents the maximal
fluorescence increase as a function of time. The data are expressed as the difference of the total activity minus the activity in
the presence of caspase inhibitor. The assay was repeated at least twice with similar results. The differences for each
caspase activity obtained from both groups of animals were determined by Student’s t test and are indicated as aP < 0.05. and Tisdale, 1987; Lorite et al, 1998). In this study, we determined
the proteolytic activity of caspases in the skeletal muscles of
animals bearing both types of tumours. To do this, we used a panel
of caspase substrates with high specificity and the peptide
inhibitors: Z-VAD-FMK, a known inhibitor of caspases-1, -3, -4
and -7, Z-DEVD-FMK; caspases -3 and -7 and Z-IEDT-FMK;
caspases -8 and -6 (Alnemri, 1997; Livingston, 1997; Villa et al,
1997). We selected 3 animals from each group with established
weight loss (from 2 to 25%) over a period of 30 days after tumour
implantation. As shown in Table 1, the proteolytic activity to
caspases-1, -9, -8 and -3 substrates was much higher in gastrocne-
mius muscles from the animals bearing the MAC16 tumour, in
relation to that in animals bearing the MAC13 tumour. The
increases in the mean proteolytic activity varied, being 54% to© 2001 Cancer Research Campaigncaspase-1, 84% to caspase-8, 98% to caspase-3, 151% to caspase-
6 and 177% to caspase-9. The differences were statistically 
significant (P < 0.05). This increase in the proteolytic activity for
each caspase was reduced by 80 to 100% in the presence of the
peptide inhibitor specific for the caspase, or with the broad spec-
trum inhibitor Z-VAD-FMK. We could not find any protease
activity for the caspase-2 substrate Z-VDVAD-AFC in any of the
samples tested (data not shown). 
Presence of PARP-cleavage products in skeletal
muscles from cachectic mice 
As described in the literature, PARP is one of the caspase protein
substrates cleaved during apoptosis by caspases-3 and -7 (LazebnikBritish Journal of Cancer (2001) 84(8), 1135–1140
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Figure 2 Agarose gel electrophoresis of genomic DNA extracted from
gastrocnemius muscle of mice bearing the MAC13 and MAC16 tumours.
Genomic DNA was extracted by the phenol:chloroform method, fractionated
in a 2.0% TAE-agarose gel and stained with ethidium bromide. The sample in
the lane is identified with the mouse number of each group as indicated in
Table 1. The lane C shows a typical apoptotic DNA fragmentation from a
sample of WEHI-164 cell line treated with murine TNF-α for 24 h 
1 7 13 2 14 15
KDA
14
Figure 3 Western blot analysis of cytochrome c released into the cytosolic
fraction of gastrocnemius muscles from mice bearing the MAC13 and MAC16
tumours. The sample is identified with the mouse number of each group as
indicated in Table 1. The arrow at the right side points to the expected protein
size in kDa 





Figure 1 Expression of PARP and PARP cleavage products in
gastrocnemius muscle from mice bearing MAC13 and MAC16 tumours. 
A total of 120 µg of protein was electrofocused and transferred to PVDF
membrane. The Western blots were performed with rabbit polyclonal
antibody and developed with the ECL detection method. The sample in the
lane is identified with the mouse number of each group as indicated in Table 1.
Arrows at the right side point to the expected protein sizes in kDa et al, 1994). The immunoblotting (Figure 1) revealed that the PARP
(116 kDa band) and PARP fragments of relative mass of 89 kDa and
25 kDa were present only in the samples 14 (only 89 kDa) and 15 of
skeletal muscles from mice bearing the MAC16 tumour. Only the
intact protein (116 kDa) was present in the skeletal muscle from mice
bearing the MAC13 tumour. This result is in line with the response of
caspase-3 activity detected in the same samples (see Table 1). 
Lack of apoptotic profile in the fragmented genomic
DNA from skeletal muscles of cachectic and
noncachectic mice 
The gel electrophoresis of extracted DNA from both groups
of animals (Figure 2) showed that some degree of fragmentation
occurred within the samples. However, there is no evidence for
a nucleosomal ladder typical of apopotic cells. This fragmented
DNA could be the result of sample preparation. 
Release of cytochrome c into the cytoplasmic fractions
of skeletal muscle of cachectic and non-cachectic mice 
Immunoblot analyses using the cytosol fractions confirmed the
release of cytochrome c in all skeletal muscle samples (Figure 3).
This was substantially increased in the sample 7 from a mouse
bearing the MAC13 tumour. Compared with the other samples, the
samples 14 and 15 from gastrocnemius muscles of cachectic mice
had the highest levels of cytochrome c release. The data suggest
that cytochrome c release could be associated with the caspase
activation in these samples. 
DISCUSSION
The mechanism of wasting as it occurs in malignant diseases and
various pathologies is still poorly understood. The ubiquitin-British Journal of Cancer (2001) 84(8), 1135–1140proteasome proteolytic pathway is of major importance in the
breakdown of skeletal muscle proteins (Lecker et al., 1999) and
has been found to be enhanced in mice bearing the MAC 16
tumour (Lorite et al., 1998). It is conceivable that a small
percentage of apoptotic cell death, in which proteases known as
caspases, play a pivotal role, could be relevant in the muscle
wasting in cancer cachexia. Our results provide the first demon-
stration, not only of caspase-like activity in skeletal muscles, but
also of a significant increase in the activity of caspase-1, 3, 8 and 9
in the skeletal muscle from mice bearing a cachexia-inducing
tumour and weight loss up to 25%. Activation of proteases suports
the phenomenon of apoptosis in the gastrocnemius muscle of
tumour-bearing mice. However, it is not known if the caspase-like
activity is related to cell death, as we did not find evidence for
DNA fragmentation into a nucleosomal ladder typical of apop-
tosis. Hints that apoptosis involving skeletal muscle cells may
occurs by routes that differ at least morphologically from other
cells have been provided (Narula et al., 1999). Certainly apoptosis
seems to play a role in atrophy of slow skeletal muscle in chronic
heart failure (Libera et al., 1999) and muscle damage after mild
exercise (Sandri et al., 1995). Also van Royen et al. (2000) have© 2001 Cancer Research Campaign
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different experimental models of cancer cachexia, the rat Yoshida
AH-130 ascites hepatoma and the mouse Lewis lung carcinoma,
suggesting an apoptotic phenomenon.
We do not know what mechanism could be involved in the acti-
vation of the caspase cascade in muscle tissue of mice bearing the
MAC16 tumour. Pro-caspase resides prodominantly inside mito-
chondria in some tissues in vivo, including cardiomyocytes and
skeletal muscles (Narula et al., 1999; Reed and Paternostro, 1999).
It was interesting to find that the presence of an increased caspase-
9-like activity (177% increase) in the cytosol of cachectic muscle
cells (samples 14 and 15) was associated with a substantial release
of cytochrome c into the cytosol (Figure 3). Thus, our interpreta-
tion is that this enzyme was activated after mitochondrial release
of cytochrome c into the cytosol, where it binds to Apaf-1 and pro-
caspase-9, resulting in caspase-9 activation, which mediated the
activation of pro-caspase-3 and -6. The cytochrome c is released
by a wide variety of stimuli through the formation of holes, tears or
pores in the mitochondrial outer membrane (Mignotte and
Vayssiere, 1998). Loss of oxidative phosphorylation and the gener-
ation of reactive oxygen species are often consequences associated
with cytochrome c release. A recent study provided evidence that
skeletal muscle from tumour-bearing mice have an abnormally
low mitochondrial chain activity and significantly decreased
glutathione levels (Ushmorov et al, 1999). Though uncertain as to
its relevance, caspases can also cause mitochondrial dysfunction
and release of cytochrome c (Mignotte and Vayssiere, 1998;
Bossy-Wetzel and Green, 1999). 
Cleavage of PARP is a strong indicative of caspase-3 activation
(Lazebnik et al, 1994; Cryns and Yuan, 1998). In our experiments
(Table 1), high amounts of caspase-3-like activity occurred in the
muscle samples with PARP cleavage. We do not know if PARP
was activated in response to tumour growth or DNA damage
caused by its products or events in the muscle tissue. Relaxation of
chromatin, following poly (ADP-ribosyl)ation of histones and
other nuclear proteins, facilitates DNA regulatory and repair
events (Pieper et al, 1999). The dual pattern of 89 kDa and 25 kDa
fragmentation of PARP has been noted after γ-irradiation and
chemotherapy induced apoptosis in many tissues and cells.
However, PARP –/– cells exhibit normal susceptibility to apop-
totic-inducing agents. 
We believe that circulating endogenous factors could have
either a direct or indirect effect on the skeletal caspase activation
pathway, with or without a pro-apoptotic effect. The family of
cytokines, which includes TNF and Fas/CD95L, mediates
caspase-activation by interacting with death receptors directly
linked to caspase-8, which activate caspase-3 (Ashkenazi and
Dixit, 1998). New members of this family of receptors has been
described but their ligands are unknown (Ashkenazi and Dixit,
1998). The DR3, DR4 and DR5 are expressed in several tissues,
including muscle tissues, suggesting that this may be relevant to
muscle cell physiology. 
Despite a strong relationship between the caspase activation and
apoptosis, there are other possibilities for their role in normal cell
functioning (Miossec et al, 1997; Nicholson and Thornberry, 1997).
Caspase-1, a member of the inflammatory caspases, which include
caspases 4, 5, 11 and 12, is involved in IL-1β activation and function,
and its inhibition reduces inflammation in various animal models.
There is no information on what happens with the degraded frag-
ments, which accumulate inside cells during the effectors caspase-
directed proteolysis. We postulate that they are further degraded© 2001 Cancer Research Campaignvia the ubiquitin-proteosome proteolytic pathway to generate
essential amino acids and nutrients with important roles in regulating
physiologic function of tissues and the whole organism. Our data
suggest that this mechanism appears to be operative in response to
tumour growth and may contribute to reduced lean body mass. 
The present study provides a first step in delineating the role of
caspases in cancer cachexia. 
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